Resistance to activated protein C caused by factor V Leiden mutation and orthotopic liver transplantation

Transplantation

Volumn 79, Issue 10, 2005, Pages 1422-1427

  Loew, Andreas ^a,b   Jacob, Dietmar ^a   Neuhaus, Peter ^a   Riess, Hanno ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Orthotopic liver transplantation; Resistance to activated protein C; Venous thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; DISEASE PREDISPOSITION; FEMALE; FOLLOW UP; FV GENE; GENE; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HUMAN; LIVER GRAFT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; VENOUS THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGED; FACTOR V; FEMALE; GENE FREQUENCY; GLUTAMINE; HETEROZYGOTE; HUMANS; INCIDENCE; LIVER TRANSPLANTATION; MALE; MEDICAL RECORDS; MIDDLE AGED; MUTATION; RISK FACTORS; SURVIVAL ANALYSIS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 19644384212     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000158021.66004.19     Document Type: Article

References (19)

1. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993 1; 90(3): 1004-1008.
2. Bertina RM, Koeleman BPC, Koster T. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
3. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
4. Riewald M, Hinz G, Ritter M, et al. High sensitivity and specificity of a coagulant essay for the detection of heterozygous and homozygous factor V Leiden-based resistance to activated protein C. Blood 1996; 88(11): 4398-4399.
5. Hintz G, Riess H, Huhn D. Inactivation of accelerin determines resistance to activated protein C. Clin Lab 1995 41: 113.
6. Svensson PJ, Zoller B, Dahlback B. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997; 77: 332-335.
7. Foster PA, Varma RR. Phenotypic correction of activated protein C resistance following orthotopic liver transplantation. Blood Coagul Fibrinolysis 1996; 7(1): 65-68.
8. Estellés A, Villa P, Mira Y, et al. Factor V Leiden in absence of activated protein C resistance after orthotopic liver transplantation in a patient without thrombosis but with familial thrombophilia. Haematologica 2000; 85(1): 111-112.
9. De Mitrio V, Amriano R, Rendina M, et al. Is activated protein C resistance following orthotopic liver transplantation a risk factor for venous Thrombosis? Blood Coagul Fibrinolysis 1999; 10(4): 211-212.
10. Parker J, Pagliuca A, Kitiyakara T, et al. Discrepancy between phenotype and genotype on screening for factor V Leiden after transplantation. Blood 2001 15; 97(8): 2525-2526.
11. Ehrenforth S, Hinke S, von Depka Prondzinski M, et al. Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population. Dtsch Med Wochenschr. 1999 25; 124(25-26): 783-787.
12. Ridker PM, Miletich JP, Hennekens CH, et al. Ethnic distribution of factor V Leiden in 4047 men and women: implications for venous thromboembolism screening. JAMA. 1997; 277: 1305-1307.
13. Clark P, Walker ID. The phenomenon known as acquired activated protein C resistance. Br J Haematol 2001; 115(4): 767-773.
14. Mahmoud AE, Elias E, Beauchamp N, et al. Prevalence of the factor V Leiden mutation and portal vein thrombosis. Gut 1997; 40(6): 798-800.
15. Janssen HLA, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000 1; 96(7): 2364-2368.
16. Hirshfield G, Collier JD, Brown K, et al. Donor factor V Leiden mutation and vascular thrombosis following liver transplantation. Liver Transpl Surg 1998; 4(1): 58-61.
17. Biesma HD, De Man AR, Nieuwenhius HK, et al. Recurrent venous thrombosis despite correction of activated Protein C resistance following orthotopic liver transplantation. Thromb Haemost 1998; 80(3): 525-526.
18. Camire RM, Pollak ES, Kaushansky K, et al. Secretable human platelet-derived factor V originates from the plasma pool. Blood 1998 1; 92(9): 3035-3041.
19. Dahlbäck B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by ArG 506 to Gln Mutation in FV as a pathogenetic risk factor for venous thrombosis. Thromb Haemost 1995; 74(1): 139-148.